Indoles

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-c

• wherein
• R1 is H,
• C1-12-alkyl, optionally substituted with CN or OH,
• C1-6-haloalkyl,
• C2-12-alkenyl,
• —(CRiRii)m—Ra,
• wherein Ri and Rii are independently from each other H, methyl, or ethyl;
• wherein m is from 0 to 4;
• wherein Ra is
• phenyl, 5- to 6-membered heteroaryl, 3- to 7-membered heterocycloalkyl or 3 to 7-membered cyloalkyl,
• which are optionally substituted with one or more A, or
• —NRbRc, wherein Rb and Rc are each independently hydrogen,
• hydroxy,
• C1-6-alkyl,
• —S(O)2—C1-6-alkyl, or
• —C(O)—C1-6-alkyl,
• —(CRiiiRiv)n—C(O)Rd,
• wherein Riii and Riv are independently from each other H, methyl, or ethyl;
• wherein n is from 0 to 4;
• wherein Rd is
• C1-6-alkoxy,
• —NReRf, wherein Re and Rf are each independently
• hydrogen,
• C1-6-alkyl, or
• —(C2-6-alkylene)NRgRh;
• wherein Rg and Rh are each independently hydrogen, C1-6-alkyl, or —C(O)O—C1-6-alkyl,
• phenyl, 5- to 6-membered heteroaryl, 3- to 7-membered heterocycloalkyl or 3 to 7-membered cyloalkyl,
• which are optionally substituted with one or more A,
• —S(O)2-phenyl, wherein phenyl is optionally substituted with one or more halo, C1-6-haloalkyl, C1-6-alkyl, C1-6-alkoxy, C1-6-haloalkoxy, nitro, hydroxy or cyano;
• —S(O)2—C1-6-alkyl,
• —S(O)2N(C1-6-alkyl)2,
• —S(O)2NH(C1-6-alkyl);
• A is halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, C1-6-cyanoalkyl, C1-6-alkoxy, C1-6-haloalkoxy, —S(O)0-2C1-6-alkyl, nitro, hydroxy, cyano, —(C1-6-alkylene)-O—C1-6-alkyl, —(C1-6-alkylene)-O—C1-6-haloalkyl, —(C1-6-alkylene)-OR′″, —C(O)OC1-6-alkyl, —C(O)C1-6-alkyl, —C(O)OR′″, —C(O)R′″, —C(O)NR′R″, —S(O)2NR′R″, —(CH2)x—NR′R″, —(CH2)x—NR′C(O)—C1-6-alkyl, —(CH2)x—NR′S(O)2—C1-6-alkyl, —(CH2)x—C3-6-cycloalkyl, —(CH2)x—R′″,
• wherein x is from 0 to 4,
• R′ and R″ are each independently H or C1-6-alkyl, or
• R′ and R″ together with the nitrogen to which they are bound form a
• 5 or 6-membered heterocycle comprising one or two heteroatoms selected from N, O and S, and
• R′″ is phenyl or 5- to 6-membered heteroaryl, optionally substituted with one, two, or three halo, C1-6-haloalkyl, C1-6-alkyl, or C1-6-alkoxy,
• R2 is hydrogen,
• C1-6-alkyl,
• —C(O)Rn, wherein Rn is
• C1-6-alkyl,
• 3 to 7-membered heterocycloalkyl, optionally substituted with one, two or three C1-6-alkyl, —C(O)O—C1-6-alkyl, or —S(O)2—C1-6-alkyl,
• NRjRk, wherein Rj and Rk are each independently
• hydrogen,
• C1-6-alkyl,
• —(C2-6-alkylene)-NRlRm;
• wherein Rl and Rm are each independently hydrogen, C1-6-alkyl, or —C(O)O—C1-6-alkyl;
• or
• R1 together with R2 forms a 5- to 6-membered heterocycloalkyl moiety fused to the indole core, bearing one or two ring heteroatoms selected from N, S and O, and being optionally substituted by one or more A;
• R3, R4, R5, R6 are each independently hydrogen, halo, C1-6-alkyl, halo-C1-6-alkyl, C1-6-alkoxy or C1-6-haloalkoxy;
• R7, R8, R9, R10 are each independently hydrogen, halo, C1-6-alkyl, halo-C1-6-alkyl, C1-6-alkoxy or C1-6-haloalkoxy;
• or a pharmaceutically acceptable salt thereof,
• with the proviso that compounds wherein R1, R2, R3, R4, R5 and R6 are all simultaneously hydrogen are excluded.